Clinical Trials Logo

Clinical Trial Summary

PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST)

- The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the sedation of agitated patients in the prehospital environment

- The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1

o The RASS is a well validated standardized score to measure a patient's agitation

- The secondary outcomes are

- Time until RASS returns to 0 or 1 if RASS <0

- Need for additional sedation

- Adverse effects (need for intubation, arrhythmia)

- Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying haloperidol

- Identification of potential study patients will be per state protocols

- Exclusion Criteria for the study

- Age <18

- Pregnant

- Allergic to study medication

- Transport to hospital other than Mercy Fitzgerald Hospital

- Unable to reach medical command prior to giving medication

- When a paramedic identifies a possible study candidate, the paramedic will consult medical command to see if the patient is appropriate for the study

- If the medical command agrees the patient is appropriate for the study, patients will be randomized to

- Odd days: Haloperidol 5mg IM (age <65) or haloperidol 2.5 mg IM (age ≥65)

- Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age <65) or maximum of 2.5mg (age ≥65)

- The RASS will be documented by the prehospital providers every 5 minutes until arrival at the hospital

- Once the patient arrives at the ED, the RASS will be documented in PICIS® by the emergency department nurse at the time of triage and at a minimum of hourly until the RASS =0 or 1 for 2 consecutive hours

- Questions may be directed to Dr. Isenberg at disenberg@mercyhealth.org or at (267) 205-6453

Richmond Agitation Sedation Scale

RASS RASS Description

- 4 Combative, violent, danger to staff

- 3 Pulls or removes tube(s) or catheters; aggressive

- 2 Frequent non-purposeful movement

- 1 Anxious, apprehensive, but not aggressive 0 Alert and calm

- 1 Awakens to voice (eye opening/contact) >10 sec

- 2 Light sedation, briefly awakens to voice (eye opening/contact) <10 sec

- 3 Moderate sedation, movement or eye opening. No eye contact

- 4 Deep sedation, no response to voice, but movement or eye opening to physical stimulation

- 5 Unarousable, no response to voice or physical stimulation


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01501123
Study type Interventional
Source Catholic Health East
Contact
Status Completed
Phase N/A
Start date November 2011
Completion date December 2015

See also
  Status Clinical Trial Phase
Completed NCT02525991 - Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT01976754 - Safety Study of Dexmedetomidine in Septic Patients N/A
Completed NCT01217541 - Collaboration Between Department of Old Age Psychiatry and Nursing Homes N/A
Withdrawn NCT00786318 - Ziprasidone vs Standard Therapy for Agitated Patients in the ED Phase 4
Not yet recruiting NCT05974527 - Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department Phase 4
Not yet recruiting NCT05522647 - Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients.
Recruiting NCT02590744 - Effects of Preoperative Using of Eye Patches on Prevention of Emergence Agitation After Cataract Surgery N/A
Recruiting NCT02164773 - Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation. Phase 4
Completed NCT01524367 - Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery Phase 4
Completed NCT01021696 - Pain in Patients With Dementia and Behavioural Disturbances Phase 2/Phase 3
Recruiting NCT05397639 - Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Phase 3
Terminated NCT03044249 - A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression Phase 2
Completed NCT05165914 - Midazolam Effect on Agitation Postnasal Surgery N/A
Completed NCT04010305 - Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia Phase 1
Completed NCT02720705 - Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children Phase 2/Phase 3
Completed NCT02428283 - Scalp Nerve Block on Emergence Agitation Phase 4
Completed NCT00457366 - A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Phase 4
Terminated NCT00315900 - Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia Phase 3
Completed NCT01848158 - Acupuncture to Improve Comfort of Children on a Ventilator in the Intensive Care Unit N/A